Warning letter
Outin Futures Corp.: warning letter of Sep 25, 2024
FDA warning letter 684688 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 684688 |
|---|---|
| Company | Outin Futures Corp. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated/Misbranded |
| Issue date | Sep 25, 2024 |
| Posted date | Oct 15, 2024 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 201.128, 211.34, 330, 211.22(a), 211.68(b), 211.100(a), 211.194(a) |
| Inspection city | Chungju |
| Inspection start date | Mar 25, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: